{"id":16630,"date":"2026-11-11T09:21:04","date_gmt":"2026-11-11T09:21:04","guid":{"rendered":"https:\/\/financialnewsspot.com\/?p=16630"},"modified":"2026-11-11T09:21:09","modified_gmt":"2026-11-11T09:21:09","slug":"epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/financialnewsspot.com\/?p=16630","title":{"rendered":"Epitopea Announces First Patient Dosed in OVACT Phase 1\/1b Clinical Trial of CryptiVax&#x2122;-1001 in Advanced High-Grade Serous Ovarian Cancer"},"content":{"rendered":"<div style=\"text-align:center\"><\/div><p> <br \/>\n<\/p>\n<p class=\"wp-block-paragraph\"><strong>CAMBRIDGE, UK and MONTREAL, CANADA, 9 November 2026<\/strong> \u2013 Epitopea, a clinical-stage, biotech company developing off-the-shelf, durable RNA-based cancer vaccines, announced today that the first patient has been successfully dosed in OVACT, its first-in-human Phase 1\/1b clinical trial evaluating its lead program, CryptiVax&#x2122;-1001, targeting advanced high-grade serous ovarian cancer (HGSOC).<\/p>\n<p class=\"wp-block-paragraph\"><a target=\"_blank\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT07665515\" target=\"_blank\" rel=\"noopener\">OVACT<\/a> is a Phase 1\/1b dose escalation trial designed to evaluate the safety, tolerability, immunogenicity, and early clinical activity of CryptiVax&#x2122;-1001 in HRP+\/BRCA-wildtype advanced HGSOC patients. Up to 30 women will be enrolled into the trial across up to 10 leading clinical centres in the UK.<\/p>\n<p class=\"wp-block-paragraph\">HGSOC remains one of the most difficult-to-treat solid tumors, with around 80% of patients presenting with advanced or metastatic disease. While most women respond to first-line platinum chemotherapy, nearly all ultimately relapse and progress to platinum-resistant disease. Existing maintenance options are only effective in half of the ovarian cancer population and leave a major therapeutic gap among HRP+\/BRCA-wildtype patients.<\/p>\n<p class=\"wp-block-paragraph\">Dr. Klaus Edvardsen, MD, PhD, Chief Medical Officer of Epitopea, commented, \u201cHGSOC is the most common and aggressive subtype of ovarian cancer. Treating the first patient with CryptiVax&#x2122;-1001 in our OVACT Phase 1\/1b trial for HGSOC is a major milestone for Epitopea. Epitopea\u2019s approach targets a novel repertoire of tumor-specific antigens that have been selected to provide broader patient benefit. We are motivated by the potential to provide meaningful durable treatment options for this underserved patient population.\u201d<\/p>\n<p class=\"wp-block-paragraph\">Professor Susana Banerjee (MBBS MA PhD FRCP), the Chief Investigator of Epitopea\u2019s OVACT trial, Consultant Medical Oncologist and Research Lead for the Gynaecology Unit at The <a target=\"_blank\" href=\"https:\/\/www.royalmarsden.nhs.uk\/\" target=\"_blank\" rel=\"noopener\">Royal Marsden<\/a> NHS Foundation Trust and Professor in Women\u2019s Cancers at The Institute of Cancer Research, London, said, \u201cIt is exciting to offer patients the option of the OVACT trial and I am delighted that we are underway with the first patient treated. The CryptiVax&#x2122;-1001 vaccine has the potential to meaningfully extend remission for women where currently available maintenance therapies deliver limited durable benefit.\u201d<\/p>\n<p class=\"wp-block-paragraph\"><strong>ENDS<\/strong><\/p>\n<p class=\"wp-block-paragraph\"><strong>About Epitopea<\/strong><\/p>\n<p class=\"wp-block-paragraph\">Epitopea is a clinical-stage cancer immunotherapy company developing accessible, off-the-shelf RNA-based immunotherapies for hard-to-treat solid tumors.<\/p>\n<p class=\"wp-block-paragraph\">Epitopea\u2019s pipeline is enabled by CryptoMap<sup>TM<\/sup>, a proprietary discovery engine that empirically identifies tumor-presented antigens arising from the dark genome, a previously inaccessible source of novel, tumor-specific targets. These antigens, known as Cryptigens<sup>TM<\/sup>, demonstrate high inter-patient sharing, enabling development of true off-the-shelf mRNA immunotherapies.<\/p>\n<p class=\"wp-block-paragraph\">The company\u2019s lead candidate, CryptiVax&#x2122;-1001, is in the multi-centre Phase 1\/1b OVACT clinical trial for high-grade serous ovarian cancer. It is designed to drive targeted immune responses using a set of tumor-specific antigens chosen for their immunogenicity and broad patient coverage. Many patients with advanced cancers, including those with high-grade serous ovarian cancer, have limited treatment options offering durable responses, with few effective therapies available beyond those in biomarker-selected populations. Epitopea aims to address this considerable unmet need with broadly applicable, tumor-selective mRNA immunotherapies.<\/p>\n<p class=\"wp-block-paragraph\">Backed by leading life-science investors, Epitopea operates from Cambridge, UK, and Montreal, Canada. For more information, visit\u202f<a target=\"_blank\" href=\"https:\/\/www.epitopea.com\/\">www.epitopea.com<\/a>\u202fand follow the company on\u202f<a target=\"_blank\" href=\"https:\/\/www.linkedin.com\/company\/epitopea\/\" target=\"_blank\" rel=\"noopener\">LinkedIn<\/a>.<\/p>\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-794e3cfa wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a target=\"_blank\" class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/admarebio.com\/en\/building-companies\/portfolio\/\">Discover our portfolio companies<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"wp-block-paragraph\">\n<p>The post <a target=\"_blank\" href=\"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/\">Epitopea Announces First Patient Dosed in OVACT Phase 1\/1b Clinical Trial of CryptiVax&#x2122;-1001 in Advanced High-Grade Serous Ovarian Cancer<\/a> appeared first on <a target=\"_blank\" href=\"https:\/\/admarebio.com\/en\/\">adMare<\/a>.<\/p>\n<p><br \/>\n<br \/><a href=\"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, UK and MONTREAL, CANADA, 9 November 2026 \u2013 Epitopea, a clinical-stage, biotech company developing off-the-shelf, durable RNA-based cancer vaccines, announced today that the first patient has been successfully dosed in OVACT, its first-in-human Phase 1\/1b clinical trial evaluating its lead program, CryptiVax&#x2122;-1001, targeting advanced high-grade serous ovarian cancer (HGSOC). OVACT is a Phase 1\/1b [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":16631,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"tdm_status":"","tdm_grid_status":"","fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[63],"tags":[],"class_list":["post-16630","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health"],"acf":[],"_links":{"self":[{"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/posts\/16630","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16630"}],"version-history":[{"count":1,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/posts\/16630\/revisions"}],"predecessor-version":[{"id":16632,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/posts\/16630\/revisions\/16632"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/media\/16631"}],"wp:attachment":[{"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16630"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16630"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16630"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}